Yunnan Baiyao Group Co Ltd - Asset Resilience Ratio
Yunnan Baiyao Group Co Ltd (000538) has an Asset Resilience Ratio of 8.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Yunnan Baiyao Group Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Yunnan Baiyao Group Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Yunnan Baiyao Group Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Yunnan Baiyao Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Yunnan Baiyao Group Co Ltd (000538) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.47 Billion | 8.38% |
| Total Liquid Assets | CN¥4.47 Billion | 8.38% |
Asset Resilience Insights
- Limited Liquidity: Yunnan Baiyao Group Co Ltd maintains only 8.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yunnan Baiyao Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Yunnan Baiyao Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.24% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Vetoquinol
PA:VETO |
Drug Manufacturers - Specialty & Generic | 1.45% |
Annual Asset Resilience Ratio for Yunnan Baiyao Group Co Ltd (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Yunnan Baiyao Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.81% | CN¥2.55 Billion ≈ $372.72 Million |
CN¥52.91 Billion ≈ $7.74 Billion |
+4.54pp |
| 2023-12-31 | 0.28% | CN¥149.37 Million ≈ $21.86 Million |
CN¥53.78 Billion ≈ $7.87 Billion |
-4.25pp |
| 2022-12-31 | 4.53% | CN¥2.42 Billion ≈ $353.50 Million |
CN¥53.32 Billion ≈ $7.80 Billion |
-4.50pp |
| 2021-12-31 | 9.03% | CN¥4.72 Billion ≈ $690.71 Million |
CN¥52.29 Billion ≈ $7.65 Billion |
-11.31pp |
| 2020-12-31 | 20.33% | CN¥11.23 Billion ≈ $1.64 Billion |
CN¥55.22 Billion ≈ $8.08 Billion |
+2.57pp |
| 2019-12-31 | 17.76% | CN¥8.82 Billion ≈ $1.29 Billion |
CN¥49.66 Billion ≈ $7.27 Billion |
-6.15pp |
| 2018-12-31 | 23.92% | CN¥7.26 Billion ≈ $1.06 Billion |
CN¥30.38 Billion ≈ $4.45 Billion |
-0.45pp |
| 2017-12-31 | 24.36% | CN¥6.75 Billion ≈ $987.65 Million |
CN¥27.70 Billion ≈ $4.05 Billion |
+16.22pp |
| 2016-12-31 | 8.14% | CN¥2.00 Billion ≈ $293.00 Million |
CN¥24.59 Billion ≈ $3.60 Billion |
-7.62pp |
| 2015-12-31 | 15.77% | CN¥3.04 Billion ≈ $445.07 Million |
CN¥19.29 Billion ≈ $2.82 Billion |
+13.10pp |
| 2014-12-31 | 2.67% | CN¥436.37 Million ≈ $63.85 Million |
CN¥16.34 Billion ≈ $2.39 Billion |
+2.67pp |
| 2013-12-31 | 0.00% | CN¥149.76K ≈ $21.91K |
CN¥12.88 Billion ≈ $1.88 Billion |
0.00pp |
| 2011-12-31 | 0.01% | CN¥519.68K ≈ $76.05K |
CN¥9.09 Billion ≈ $1.33 Billion |
-0.02pp |
| 2006-12-31 | 0.03% | CN¥587.23K ≈ $85.93K |
CN¥2.19 Billion ≈ $320.67 Million |
+0.01pp |
| 2005-12-31 | 0.01% | CN¥239.41K ≈ $35.03K |
CN¥1.60 Billion ≈ $234.20 Million |
-0.08pp |
| 2004-12-31 | 0.09% | CN¥1.19 Million ≈ $174.33K |
CN¥1.27 Billion ≈ $185.96 Million |
+0.07pp |
| 2003-12-31 | 0.02% | CN¥248.88K ≈ $36.42K |
CN¥1.05 Billion ≈ $153.02 Million |
-0.01pp |
| 2002-12-31 | 0.03% | CN¥306.44K ≈ $44.84K |
CN¥920.65 Million ≈ $134.72 Million |
-0.02pp |
| 2001-12-31 | 0.05% | CN¥416.78K ≈ $60.99K |
CN¥843.99 Million ≈ $123.50 Million |
-0.77pp |
| 2000-12-31 | 0.82% | CN¥6.53 Million ≈ $955.00K |
CN¥792.85 Million ≈ $116.02 Million |
+0.66pp |
| 1999-12-31 | 0.16% | CN¥1.25 Million ≈ $183.46K |
CN¥761.62 Million ≈ $111.45 Million |
-0.71pp |
| 1998-12-31 | 0.88% | CN¥3.09 Million ≈ $452.77K |
CN¥351.99 Million ≈ $51.51 Million |
+0.70pp |
| 1997-12-31 | 0.18% | CN¥565.84K ≈ $82.80K |
CN¥315.44 Million ≈ $46.16 Million |
-7.32pp |
| 1996-12-31 | 7.50% | CN¥19.45 Million ≈ $2.85 Million |
CN¥259.26 Million ≈ $37.94 Million |
-19.63pp |
| 1995-12-31 | 27.14% | CN¥66.80 Million ≈ $9.77 Million |
CN¥246.17 Million ≈ $36.02 Million |
-2.89pp |
| 1994-12-31 | 30.03% | CN¥60.30 Million ≈ $8.82 Million |
CN¥200.83 Million ≈ $29.39 Million |
+16.98pp |
| 1993-12-31 | 13.05% | CN¥23.00 Million ≈ $3.37 Million |
CN¥176.27 Million ≈ $25.79 Million |
-- |
About Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China. The company offers health products; drugs; chemical raw materials, chemical preparations, sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, medical devices, health food, food, beverages, special labor protection products, production and sales … Read more